- Details
- Renu Eapen, a recipient of the PCF Young Investigator Award, details her groundbreaking project on early use of Lutetium PSMA for high-risk localized prostate cancer. The two-cohort clinical trial involves administering Lutetium PSMA upfront, followed by radical prostatectomy. An integral part of the study is the translational work, analyzing changes in the tumor microenvironment in response to Lu...
|
- Details
- Leanne Woods-Burnham discusses her 2020 Young Investigator Award project with the Prostate Cancer Foundation, focusing on prostate cancer disparities, especially among black men. Her research looks at HER2 expression and its connection to West African ancestry. She explains that HER2 is correlated with this ancestry, rather than self-reported race. The project involves RNA sequencing on tumor tiss...
|
- Details
- Alicia Morgans speaks with Sophia Kamran, who won the Young Investigator Award in 2021. Dr. Kamran shares her research into the potentially beneficial role of radiation in treating oligometastatic prostate cancer, a field where much remains unknown. She is particularly focused on defining the disease more biologically, while also examining the complex interaction of radiation with the immune syste...
|
- Details
- Kara Maxwell shares insights about the groundbreaking work she and her team have been undertaking in germline genetic testing. Supported by PCF funds, they aim to bolster genetic testing programs for patients within the VA system and beyond. Notably, Dr. Maxwell praises the contributions of her colleague, Dr. Lisa Aiello, a skilled PhD-trained nurse, who has been instrumental in establishing a poi...
|
- Details
- Alicia Morgans and Tia Higano discuss the PRONOUNCE trial, which evaluates the effects of degarelix and leuprolide on cardiovascular events in high-risk prostate cancer patients. Dr. Higano offers insightful explanations concerning the trial's methodology, highlighting its initial slow accrual and early cessation due to a futility analysis. However, she points out that the trial's results, which s...
|
- Details
- Neal Shore shares insights from his presentation about the PROCLAIM trial - a study examining the impact of germline genetic testing on prostate cancer clinical decisions. Dr. Shore underscores the importance of expanding testing beyond traditional criteria, given the prevalence of pathogenic germline variants among both qualifying and non-qualifying patients under NCCN criteria. Notably, the tria...
|
- Details
- Alicia Morgans engages with Joaquin Mateo to discuss the clinically relevant challenges and approaches to somatic mutation testing in advanced prostate cancer patients. They address the difficulties in obtaining adequate tissue for testing, the concordance between different testing mechanisms, and the balance between ideal plans and clinical feasibility. Dr. Mateo emphasizes the importance of unde...
|
- Details
- Alicia Morgans speaks with Felix Feng about his pioneering work in prostate cancer, specifically focusing on the integration of artificial intelligence (AI) to enhance understanding of pathology. Dr. Feng emphasizes that AI technology is already here and is being utilized to leverage extensive information about prostate cancer to make better-personalized decisions regarding patient care. He highli...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss The Journal of Clinical Oncology publication entitled, "Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial." This trial evaluated the treatment effect of adding docetaxel to ADT + radiation therapy on the primary end point of overall...
|
- Details
- Eric Small presents a discussion on primary small cell prostate cancer and therapeutic approaches to consider in aggressive variant prostate cancer (AVPC) and small cell neuroendocrine prostate cancer (t-SCNC) patients. Biographies: Eric Small, MD, Doris and Donald Fisher Distinguished Professorship in Clinical Cancer Research; Stanford W. Ascherman and Norman R. Ascherman Endowed Chair, UCSF, Pro...
|
